Patents by Inventor Patrick F. Kelly

Patrick F. Kelly has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Inhibiting mutant isocitrate dehydrogenase 1 (mIDH-1)
    Patent number: 11963956
    Abstract: Patients diagnosed with a cancer harboring an IDH-1 mutation can be treated by the administration of a therapeutically effective amount of a pharmaceutical composition comprising Compound 1, a selective inhibitor of 2-HG production from mIDH-1 enzymes including the R132 mutations R132C, R132H, R132L, R132G, and R132S.
    Type: Grant
    Filed: March 21, 2022
    Date of Patent: April 23, 2024
    Assignee: FORMA Therapeutics, Inc.
    Inventors: Patrick F. Kelly, Susan Ashwell, Blythe Thomson, Alan Collis, Jeff Davis, Duncan Walker, Wei Lu
  • Inhibiting mutant isocitrate dehydrogenase 1 (mIDH-1)
    Patent number: 11738018
    Abstract: Patients diagnosed with a cancer harboring an IDH-1 mutation can be treated by the administration of a therapeutically effective amount of a pharmaceutical composition comprising Compound 1, a selective inhibitor of 2-HG production from mIDH-1 enzymes including the R132 mutations R132C, R132H, R132L, R132G, and R132S.
    Type: Grant
    Filed: April 28, 2021
    Date of Patent: August 29, 2023
    Assignee: FORMA Therapeuetics, Inc.
    Inventors: Susan Ashwell, Blythe Thomson, Patrick F. Kelly, Alan Collis, Jeff Davis, Duncan Walker, Wei Lu
  • TREATING PATIENTS HARBORING AN ISOCITRATE DEHYDROGENASE-1 (IDH-1) MUTATION
    Publication number: 20230101121
    Abstract: Methods of treating patients diagnosed with AML or MDS harboring mutant IDH-1 include detecting an IDH1 mutation and the therapeutic administration of an inhibitor of a mutant IDH-1 as a single agent, or in combination with azacitidine (AZA) or cytarabine.
    Type: Application
    Filed: November 14, 2022
    Publication date: March 30, 2023
    Applicant: FORMA Therapeutics, Inc.
    Inventors: Patrick F. Kelly, Alan Collis, Jeff Davis, Duncan Walker, Susan Ashwell, Blythe Thomson, Wei Lu
  • INHIBITING MUTANT ISOCITRATE DEHYDROGENASE 1 (mIDH-1)
    Publication number: 20230066088
    Abstract: Patients diagnosed with a cancer harboring an IDH-1 mutation can be treated by the administration of a therapeutically effective amount of a pharmaceutical composition comprising Compound 1, a selective inhibitor of 2-HG production from mIDH-1 enzymes including the R132 mutations R132C, R132H, R132L, R132G, and R132S.
    Type: Application
    Filed: March 21, 2022
    Publication date: March 2, 2023
    Inventors: Patrick F. Kelly, Susan Ashwell, Blythe Thomson, Alan Collis, Jeff Davis, Duncan Walker, Wei Lu
  • Inhibiting mutant IDH-1
    Patent number: 11576906
    Abstract: Methods of treating patients diagnosed with cancer harboring an IDH-1 mutation are provided, including the therapeutic administration of a certain inhibitor of a mutant IDH-1 as a single agent, or in combination with azacitidine (AZA).
    Type: Grant
    Filed: May 16, 2019
    Date of Patent: February 14, 2023
    Assignee: FORMA Therapeutics, Inc.
    Inventors: Patrick F. Kelly, Alan Collis, Jeff Davis, Duncan Walker, Susan Ashwell, Blythe Thomson, Wei Lu
  • ACTIVATING PYRUVATE KINASE R
    Publication number: 20220378756
    Abstract: The compound (S)-1-(5-((2,3-dihydro-[1,4]dioxino[2,3-b]pyridin-7-yl)sulfonyl)-3,4,5,6-tetrahydropyrrolo[3,4-c]pyrroll-2(1H)-yl)-3-hydroxy-2-phenylpropan-1-one, or a pharmaceutically acceptable salt thereof, is useful to increase the affinity of hemoglobin for oxygen. Methods and compositions for the treatment of a hemoglobinopathies are provided herein, including certain pharmaceutical compositions for activating PKR.
    Type: Application
    Filed: September 18, 2020
    Publication date: December 1, 2022
    Inventors: Anna Ericsson, Sanjeev Forsyth, Neal Green, Gary Gustafson, Patrick F. Kelly, David R. Lancia, JR., Gary Marshall, Lorna Mitchell, Madhu Mondal, Maria Ribadeneira, David Richard, Patricia Schroeder, Zhongguo Wang
  • Treating patients harboring an isocitrate dehydrogenase 1 (IDH-1) mutation
    Patent number: 11497743
    Abstract: Methods of treating patients diagnosed with AML or MDS harboring mutant IDH-1 include detecting an IDH1 mutation and the therapeutic administration of an inhibitor of a mutant IDH-1 as a single agent, or in combination with azacitidine (AZA) or cytarabine.
    Type: Grant
    Filed: December 4, 2020
    Date of Patent: November 15, 2022
    Assignee: FORMA Therapeutics, Inc.
    Inventors: Patrick F. Kelly, Alan Collis, Jeff Davis, Duncan Walker, Susan Ashwell, Blythe Thomson, Wei Lu
  • ACTIVATING PYRUVATE KINASE R
    Publication number: 20220304987
    Abstract: The compound (S)-1-(5-((2,3-dihydro-[1,4]dioxino[2,3-b]pyridin-7-yl)sulfonyl)-3,4,5,6-tetrahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)-3-hydroxy-2-phenylpropan-1-one, or a pharmaceutically acceptable salt thereof, is useful to increase the affinity of hemoglobin for oxygen. Methods and compositions for the treatment of a hemoglobinopathies are provided herein, including certain pharmaceutical compositions for activating PKR.
    Type: Application
    Filed: March 18, 2022
    Publication date: September 29, 2022
    Inventors: Anna Ericsson, Neal Green, Gary Gustafson, David R. Lancia, JR., Gary Marshall, Lorna Mitchell, David Richard, Zhongguo Wang, Sanjeev Forsyth, Patrick F. Kelly, Madhu Mondal, Maria Ribadeneira, Patricia Schroeder
  • Inhibiting mutant IDH-1
    Patent number: 11376246
    Abstract: Methods of treating patients diagnosed with cancer harboring an IDH-1 mutation are provided, including the therapeutic administration of a certain inhibitor of a mutant IDH-1 as a single agent, or in combination with azacitidine (AZA).
    Type: Grant
    Filed: November 25, 2019
    Date of Patent: July 5, 2022
    Assignee: FORMA Therapeutics, Inc.
    Inventors: Patrick F. Kelly, Alan Collis, Jeff Davis, Duncan Walker, Susan Ashwell, Blythe Thomson, Wei Lu
  • Inhibiting mutant isocitrate dehydrogenase 1 (mIDH-1)
    Patent number: 11311527
    Abstract: Patients diagnosed with a cancer harboring an IDH-1 mutation can be treated by the administration of a therapeutically effective amount of a pharmaceutical composition comprising Compound 1, a selective inhibitor of 2-HG production from mIDH-1 enzymes including the R132 mutations R132C, R132H, R132L, R132G, and R132S.
    Type: Grant
    Filed: June 4, 2020
    Date of Patent: April 26, 2022
    Assignee: FORMA Therapeutics, Inc.
    Inventors: Patrick F. Kelly, Susan Ashwell, Blythe Thomson, Alan Collis, Jeff Davis, Duncan Walker, Wei Lu
  • ACTIVATING PYRUVATE KINASE R
    Publication number: 20220087983
    Abstract: The compound (S)-1-(5-((2,3-dihydro-[1,4]dioxino[2,3-b]pyridin-7-yl)sulfonyl)-3,4,5,6-tetrahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)-3-hydroxy-2-phenylpropan-1-one, or a pharmaceutically acceptable salt thereof, is useful to increase the affinity of hemoglobin for oxygen. Methods and compositions for the treatment of a hemoglobinopathies are provided herein, including certain pharmaceutical compositions for activating PKR.
    Type: Application
    Filed: September 17, 2021
    Publication date: March 24, 2022
    Inventors: Anna Ericsson, Neal Green, Gary Gustafson, David R. Lancia, JR., Gary Marshall, Lorna Mitchell, David Richard, Zhongguo Wang, Sanjeev Forsyth, Patrick F. Kelly, Madhu Mondal, Maria Ribadeneira, Patricia Schroeder
  • TREATING SICKLE CELL DISEASE WITH A PYRUVATE KINASE R ACTIVATING COMPOUND
    Publication number: 20220031671
    Abstract: Compounds that activate pyruvate kinase R can be used for the treatment of sickle cell disease (SCD). Methods and compositions for the treatment of SCD are provided herein, including a therapeutic compound designated as Compound 1.
    Type: Application
    Filed: September 19, 2019
    Publication date: February 3, 2022
    Inventors: Anna ERICSSON, Neal GREEN, Gary GUSTAFSON, David R. LANCIA, Jr., Gary MARSHALL, Lorna MITCHELL, David RICHARD, Zhongguo WANG, Sanjeev FORSYTH, Patrick F. KELLY, Madhu MONDAL, Maria RIBADENEIRA, Patricia SCHROEDER
  • INHIBITING MUTANT ISOCITRATE DEHYDROGENASE 1 (mIDH-1)
    Publication number: 20210244727
    Abstract: Patients diagnosed with a cancer harboring an IDH-1 mutation can be treated by the administration of a therapeutically effective amount of a pharmaceutical composition comprising Compound 1, a selective inhibitor of 2-HG production from mIDH-1 enzymes including the R132 mutations R132C, R132H, R132L, R132G, and R132S.
    Type: Application
    Filed: April 28, 2021
    Publication date: August 12, 2021
    Inventors: Susan ASHWELL, Blythe THOMSON, Patrick F. KELLY, Alan COLLIS, Jeff DAVIS, Duncan WALKER, Wei LU
  • INHIBITING MUTANT IDH-1
    Publication number: 20210196701
    Abstract: Methods of treating patients diagnosed with cancer harboring an IDH-1 mutation are provided, including the therapeutic administration of a certain inhibitor of a mutant IDH-1 as a single agent, or in combination with azacitidine (AZA).
    Type: Application
    Filed: May 16, 2019
    Publication date: July 1, 2021
    Inventors: Patrick F. Kelly, Alan Collis, Jeff Davis, Duncan Walker, Susan Ashwell, Blythe Thomson, Wei Lu
  • Inhibiting mutant isocitrate dehydrogenase 1 (mlDH-1)
    Patent number: 11013733
    Abstract: Patients diagnosed with a cancer harboring an IDH-1 mutation can be treated by the administration of a therapeutically effective amount of a pharmaceutical composition comprising Compound 1, a selective inhibitor of 2-HG production from mIDH-1 enzymes including the R132 mutations R132C, R132H, R132L, R132G, and R132S.
    Type: Grant
    Filed: June 4, 2019
    Date of Patent: May 25, 2021
    Assignee: FORMA Therapeutics, Inc.
    Inventors: Susan Ashwell, Blythe Thomson, Patrick F. Kelly, Alan Collis, Jeff Davis, Duncan Walker, Wei Lu
  • Treating patients harboring an isocitrate dehydrogenase-1 (IDH-1) mutation
    Patent number: 11013734
    Abstract: Methods of treating patients diagnosed with AML or MDS harboring mutant IDH-1 include detecting an IDH1 mutation and the therapeutic administration of an inhibitor of a mutant IDH-1 as a single agent, or in combination with azacitidine (AZA) or cytarabine.
    Type: Grant
    Filed: July 30, 2019
    Date of Patent: May 25, 2021
    Assignee: FORMA Therapeutics, Inc.
    Inventors: Patrick F. Kelly, Alan Collis, Jeff Davis, Duncan Walker, Susan Ashwell, Blythe Thomson, Wei Lu
  • TREATING PATIENTS HARBORING AN ISOCITRATE DEHYDROGENASE 1 (IDH-1) MUTATION
    Publication number: 20210085669
    Abstract: Methods of treating patients diagnosed with AML or MDS harboring mutant IDH-1 include detecting an IDH1 mutation and the therapeutic administration of an inhibitor of a mutant IDH-1 as a single agent, or in combination with azacitidine (AZA) or cytarabine.
    Type: Application
    Filed: December 4, 2020
    Publication date: March 25, 2021
    Inventors: Patrick F. Kelly, Alan Collis, Jeff Davis, Duncan Walker, Susan Ashwell, Blythe Thomson, Wei Lu
  • TREATING SICKLE CELL DISEASE WITH A PYRUVATE KINASE R ACTIVATING COMPOUND
    Publication number: 20200405699
    Abstract: Compounds that activate pyruvate kinase R can be used for the treatment of sickle cell disease (SCD). Methods and compositions for the treatment of SCD are provided herein, including a therapeutic compound designated as Compound 1.
    Type: Application
    Filed: September 1, 2020
    Publication date: December 31, 2020
    Inventors: Anna ERICSSON, Neal GREEN, Gary GUSTAFSON, David R. LANCIA, Jr., Gary MARSHALL, Lorna MITCHELL, David RICHARD, Zhongguo WANG, Sanjeev FORSYTH, Patrick F. KELLY, Madhu MONDAL, Maria RIBADENEIRA, Patricia SCHROEDER
  • INHIBITING MUTANT ISOCITRATE DEHYDROGENASE 1 (mIDH-1)
    Publication number: 20200297717
    Abstract: Patients diagnosed with a cancer harboring an IDH-1 mutation can be treated by the administration of a therapeutically effective amount of a pharmaceutical composition comprising Compound 1, a selective inhibitor of 2-HG production from mIDH-1 enzymes including the R132 mutations R132C, R132H, R132L, R132G, and R132S.
    Type: Application
    Filed: June 4, 2020
    Publication date: September 24, 2020
    Inventors: Patrick F. Kelly, Susan Ashwell
  • INHIBITING MUTANT IDH-1
    Publication number: 20200108060
    Abstract: Methods of treating patients diagnosed with cancer harboring an IDH-1 mutation are provided, including the therapeutic administration of a certain inhibitor of a mutant IDH-1 as a single agent, or in combination with azacitidine (AZA).
    Type: Application
    Filed: November 25, 2019
    Publication date: April 9, 2020
    Inventors: Patrick F. Kelly, Alan Collis, Jeff Davis, Duncan Walker, Susan Ashwell, Blythe Thomson